Presynaptic Regulation of Dopamine Transmission in Schizophrenia
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A role for dopamine (DA) release in the hallucinations and other positive symptoms associated with schizophrenia has long been inferred from the antipsychotic response to D2 DA receptor antagonists and because the DA releaser amphetamine can be psychotogenic. Recent studies suggest that patients with schizophrenia, including those never exposed to antipsychotic drugs, maintain high presynaptic DA accumulation in the striatum. New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Self-citationSurmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“Within patients with schizophrenia, binding was higher for those experiencing an exacerbation of illness than for those who were not experiencing a psychotic episode.(44,54) Assuming that the number and affinity of D2 receptors for DA are similar during and between psychotic episodes and that DA depletion does not alt…”
BackgroundSelf-citationUnique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., & Roeper, J. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.022 · Cited by 976
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 1×
“When exposed to amphetamine, individuals without schizophrenia who exhibit the common Met/Met COMT genotype, which leads to slower DA metabolism than seen with the Val/Val form,(71) exhibit poorer performance on high task-load tests than do those with the Val/ Val form.(73) A clinical analysis of the polymorphism in J…”
BackgroundSeeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Day, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z., Sampson, A. R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1632 · Cited by 745
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Haber, S. N., Kim, K.-S., Mailly, P., & Calzavara, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0271-06.2006 · Cited by 686
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 1×
“Interestingly, in patients with schizophrenia, decreases in prefrontal cortical activation during performance of cognitive tasks correlated with increased [(18)F]DOPA signal in the striatum.(51) As Table 1.”
BackgroundNicotine amplifies reward-related dopamine signals in striatum
Rice, M. E., & Cragg, S. J. (2004) · Nature Neuroscience · doi:10.1038/nn1244 · Cited by 594
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520 · cited 1×
“Transgenic mice overexpressing striatal DA D2 receptors show increased prefrontal cortical DA levels and decreased rates ofDA turnover as a result of a developmental compensation.(108)”
BackgroundSelf-citationNeurobiology of Dopamine in Schizophrenia
Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365 · cited 1×
“Note: Adapted from Int Rev Neurobiol 2007;78:17–20.(56) DA = dopamine; DOPA = 3,4-dihydroxyphenylalanine; IBZM = iodobenzamide; a-MPT = a-methyl-p-tyrosine; DAT = dopamine uptake transporter; ns = nonsignificant; dopamine transporter (DAT) ligand, 99mTcTRODAT-1; (18)F-radiolabelling synthesis ((18)F; T(1/2) = 109.”
Self-citationFrequency-dependent modulation of dopamine release by nicotine
Zhang, H., & Sulzer, D. (2004) · Nature Neuroscience · doi:10.1038/nn1243 · Cited by 361
Self-citationYung, A. R., Nelson, B., Stanford, C., Simmons, M. B., Cosgrave, E. M., Killackey, E., Phillips, L. J., Bechdolf, A., Buckby, J., & McGorry, P. D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.012 · Cited by 358 · cited 1×
“During the prodromal period,(66,67) individuals exhibit symptomsofdepressionor ‘‘negative symptoms’’of schizophreniaandsometimessubthresholdlevelsofpositive symptoms.(68,69) A recent [(18)F]DOPA imaging study of prodromal patients(53) compared controls, ‘‘at-risk mental state’’ (ARMS) prodromal patients, and new-onset…”
BackgroundElevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342
Boileau, I., Dagher, A., Leyton, M., Gunn, R. N., Baker, G. B., Diksic, M., & Benkelfat, C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1386 · Cited by 305
Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis
CHEN, C.-K., LIN, S.-K., SHAM, P. C., BALL, D., LOH, E.-W., HSIAO, C.-C., CHIANG, Y.-L., REE, S.-C., LEE, C.-H., & MURRAY, R. M. (2003) · Psychological Medicine · doi:10.1017/s0033291703008353 · Cited by 295 · cited 1×
“Premorbid schizoid or schizotypal personality predisposes methamphetamine users to psychosis, and the greater the personality vulnerability, the longer the psychosis persists.(20) Many patients with schizophrenia exhibit an emergence or worsening of psychotic symptoms after acute exposure to amphetamine at doses that…”
BackgroundProdromal interventions for schizophrenia vulnerability: the risks of being “at risk”
Corcoran, C., Malaspina, D., & Hercher, L. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.021 · Cited by 183
The natural history and pathophysiology of treatment resistant schizophrenia
Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140 · cited 1×
“The patients who exhibit a worsening of psychotic symptoms in response to psychostimulant challenge during acute episodes are more likely to relapse upon antipsychotic discontinuation.(22) Thus, both chronic and (1)To whom correspondence should be addressed; Department of Neurology, Columbia University, Black 309, 650…”
BackgroundSelf-citationPhasic Dopamine Signaling During Behavior, Reward, and Disease States
Wightman, R., & Heien, M. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706784111605 · Cited by 68
Cited by
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Self-citationSchizophrenia: an integrated sociodevelopmental-cognitive model
Howes, O. D., & Murray, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62036-x · Cited by 864
Sleep disturbance as transdiagnostic: Consideration of neurobiological mechanisms
Harvey, A. G., Murray, G., Chandler, R. A., & Soehner, A. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.04.003 · Cited by 609
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., Valmaggia, L., Allen, P., Murray, R., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.20 · Cited by 292
Metadata
- Authors
- Lyon, G. J., Abi-Dargham, A., Moore, H., Lieberman, J. A., Javitch, J. A., & Sulzer, D.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-12
- Volume
- 37
- Issue
- 1
- Pages
- 108-117
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2126348667
- Cited by
- 66
- References
- 29
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.